Tyra Biosciences

Historical price data

Tyra Biosciences is a clinical-stage biotech focused on developing next-generation, selective FGFR inhibitors for oncology and genetically defined skeletal conditions. Its core value proposition is its proprietary SNÅP discovery platform, which enables rapid, structure-based drug design to tackle resistance mutations and improve selectivity. The company has built a robust pipeline led by oral dabogratinib, now in Phase 2 for achondroplasia and with IND clearance for bladder cancer, supported by a strong team with deep drug development and commercialization expertise.

Proprietary SNÅP (Structure-based Nucleotide And Protein) Discovery Engine, a rapid structure-based drug design platform that accelerates crystallography and enables the iterative design of selective kinase inhibitors.

Tyra competes against approved but limited pan-FGFR inhibitors (e.g., erdafitinib, pemigatinib) and other next-generation candidates. Its differentiation is based on designed selectivity and potency against resistance mutations, aiming for best-in-class profiles in both oncology and skeletal dysplasia.